Podcasts about Obesity

Join the Conversation at 303-477-5600 or text to 307-200-8222. Monday-Friday, 3 pm-6 pm MT. https://RushToReason.com Hour 1 Stage 4 Cancer, Heart Disease, and the Health Choices That Could Change Everything. Kick off Health and Wellness Wednesday with John Rush as he dissects new revelations about Anthony Fauci and the unresolved mysteries of the COVID era. Then, plunge into two gripping, real-life stories of defying the odds—where hope, healing, and prevention take center stage. What if stage 4 cancer isn't the end—but a new beginning? Emma Victoria Johnson reveals how she turned a devastating diagnosis into a story of hope, discovering lifesaving breakthroughs at Oasis of Hope. Hear how bold lifestyle changes, nutrition, and immune health fueled her fight for recovery. Next, Wayne Elliott recounts surviving a heart attack at just 35. Discover the unconventional choices he credits with transforming his life—and what most people overlook about heart health. Obesity, statins, Alzheimer's, toxins, and the daily habits that could change your future—don't miss these life-altering insights. John wraps up with a bold question: Is our addiction to convenience silently sabotaging our health? This hour is packed with inspiring stories, frank conversations, and eye-opening ideas that might just make you rethink your everyday choices. Timestamps 11:46 — Emma Victoria Johnson — https://www.oasisofhope.com 30:38 — Wayne Elliott — https://straussnaturals.com HOUR 2 Freedom, Socialism, Fauci, and Colorado's Political Crossroads. Start with a wake-up call: Richard Battle lays out why America stands at a crossroads—can free enterprise and liberty survive in a world drifting toward socialism? Hear powerful arguments for economic freedom, plus a candid look at inflation, government overreach, and immigration. John tackles Colorado's political storm, revealing why divided conservatives could see their state slip away for good. Sunny Kutcher of Young Americans Against Socialism brings the heat, exposing the rapid rise of socialist ideas and the high stakes for government accountability. Dive into Fauci's testimony, pandemic fallout, free speech battles, and border clashes—plus, why the next Colorado election could change everything. If you care about America's future, you can't afford to miss this. Timestamps 1:09 — Richard Battle — https://RichardBattle.com 30:37 — Sunny Kutcher — https://yaas.org Hour 3 COVID Secrets, AI Showdown, and Colorado's Tech Future Hang in the Balance Uncover the untold story behind COVID lockdowns as Michael Pack reveals what went into the making of ‘Lockdown Dissidents.' Go behind the scenes with Fauci's diary, the fallout of school closures, and the fight for civil liberties. John Rush pulls back the curtain on the backlash he faced for challenging the status quo—proving why questioning authority is more important than ever. Then, shift gears as Scott Garliss breaks down the high-stakes world of Wall Street and artificial intelligence—revealing how today's tech battles could decide America's financial future. John fires back at short-sighted tech critics, champions AI innovation, and explains why your vote could shape the next era of American leadership. Timestamps 1:07 — Michael Pack — https://palladiumpictures.com/ 28:34 — Scott Garliss — https://www.bentpinecapital.com/

Join the Conversation at 303-477-5600 or text to 307-200-8222. Monday-Friday, 3 pm-6 pm MT. https://RushToReason.com Hour 1 Stage 4 Cancer, Heart Disease, and the Health Choices That Could Change Everything. Kick off Health and Wellness Wednesday with John Rush as he dissects new revelations about Anthony Fauci and the unresolved mysteries of the COVID era. Then, plunge into two gripping, real-life stories of defying the odds—where hope, healing, and prevention take center stage. What if stage 4 cancer isn't the end—but a new beginning? Emma Victoria Johnson reveals how she turned a devastating diagnosis into a story of hope, discovering lifesaving breakthroughs at Oasis of Hope. Hear how bold lifestyle changes, nutrition, and immune health fueled her fight for recovery. Next, Wayne Elliott recounts surviving a heart attack at just 35. Discover the unconventional choices he credits with transforming his life—and what most people overlook about heart health. Obesity, statins, Alzheimer's, toxins, and the daily habits that could change your future—don't miss these life-altering insights. John wraps up with a bold question: Is our addiction to convenience silently sabotaging our health? This hour is packed with inspiring stories, frank conversations, and eye-opening ideas that might just make you rethink your everyday choices. Timestamps 11:46 — Emma Victoria Johnson — https://www.oasisofhope.com 30:38 — Wayne Elliott — https://straussnaturals.com HOUR 2 Freedom, Socialism, Fauci, and Colorado's Political Crossroads. Start with a wake-up call: Richard Battle lays out why America stands at a crossroads—can free enterprise and liberty survive in a world drifting toward socialism? Hear powerful arguments for economic freedom, plus a candid look at inflation, government overreach, and immigration. John tackles Colorado's political storm, revealing why divided conservatives could see their state slip away for good. Sunny Kutcher of Young Americans Against Socialism brings the heat, exposing the rapid rise of socialist ideas and the high stakes for government accountability. Dive into Fauci's testimony, pandemic fallout, free speech battles, and border clashes—plus, why the next Colorado election could change everything. If you care about America's future, you can't afford to miss this. Timestamps 1:09 — Richard Battle — https://RichardBattle.com 30:37 — Sunny Kutcher — https://yaas.org Hour 3 COVID Secrets, AI Showdown, and Colorado's Tech Future Hang in the Balance Uncover the untold story behind COVID lockdowns as Michael Pack reveals what went into the making of ‘Lockdown Dissidents.' Go behind the scenes with Fauci's diary, the fallout of school closures, and the fight for civil liberties. John Rush pulls back the curtain on the backlash he faced for challenging the status quo—proving why questioning authority is more important than ever. Then, shift gears as Scott Garliss breaks down the high-stakes world of Wall Street and artificial intelligence—revealing how today's tech battles could decide America's financial future. John fires back at short-sighted tech critics, champions AI innovation, and explains why your vote could shape the next era of American leadership. Timestamps 1:07 — Michael Pack — https://palladiumpictures.com/ 28:34 — Scott Garliss — https://www.bentpinecapital.com/

Join the Conversation at 303-477-5600 or text to 307-200-8222. Monday-Friday, 3 pm-6 pm MT. https://RushToReason.com Hour 1 Stage 4 Cancer, Heart Disease, and the Health Choices That Could Change Everything. Kick off Health and Wellness Wednesday with John Rush as he dissects new revelations about Anthony Fauci and the unresolved mysteries of the COVID era. Then, plunge into two gripping, real-life stories of defying the odds—where hope, healing, and prevention take center stage. What if stage 4 cancer isn't the end—but a new beginning? Emma Victoria Johnson reveals how she turned a devastating diagnosis into a story of hope, discovering lifesaving breakthroughs at Oasis of Hope. Hear how bold lifestyle changes, nutrition, and immune health fueled her fight for recovery. Next, Wayne Elliott recounts surviving a heart attack at just 35. Discover the unconventional choices he credits with transforming his life—and what most people overlook about heart health. Obesity, statins, Alzheimer's, toxins, and the daily habits that could change your future—don't miss these life-altering insights. John wraps up with a bold question: Is our addiction to convenience silently sabotaging our health? This hour is packed with inspiring stories, frank conversations, and eye-opening ideas that might just make you rethink your everyday choices. Timestamps 11:46 — Emma Victoria Johnson — https://www.oasisofhope.com 30:38 — Wayne Elliott — https://straussnaturals.com HOUR 2 Freedom, Socialism, Fauci, and Colorado's Political Crossroads. Start with a wake-up call: Richard Battle lays out why America stands at a crossroads—can free enterprise and liberty survive in a world drifting toward socialism? Hear powerful arguments for economic freedom, plus a candid look at inflation, government overreach, and immigration. John tackles Colorado's political storm, revealing why divided conservatives could see their state slip away for good. Sunny Kutcher of Young Americans Against Socialism brings the heat, exposing the rapid rise of socialist ideas and the high stakes for government accountability. Dive into Fauci's testimony, pandemic fallout, free speech battles, and border clashes—plus, why the next Colorado election could change everything. If you care about America's future, you can't afford to miss this. Timestamps 1:09 — Richard Battle — https://RichardBattle.com 30:37 — Sunny Kutcher — https://yaas.org Hour 3 COVID Secrets, AI Showdown, and Colorado's Tech Future Hang in the Balance Uncover the untold story behind COVID lockdowns as Michael Pack reveals what went into the making of ‘Lockdown Dissidents.' Go behind the scenes with Fauci's diary, the fallout of school closures, and the fight for civil liberties. John Rush pulls back the curtain on the backlash he faced for challenging the status quo—proving why questioning authority is more important than ever. Then, shift gears as Scott Garliss breaks down the high-stakes world of Wall Street and artificial intelligence—revealing how today's tech battles could decide America's financial future. John fires back at short-sighted tech critics, champions AI innovation, and explains why your vote could shape the next era of American leadership. Timestamps 1:07 — Michael Pack — https://palladiumpictures.com/ 28:34 — Scott Garliss — https://www.bentpinecapital.com/

Dr. Austin Baraki joins me to challenge the popular narrative that testosterone levels are collapsing across society and to examine what the available evidence actually shows.Austin joins me to discuss:• Whether men's testosterone levels have declined dramatically in recent decades• Where the testosterone-decline narrative originated• Why viral claims often move faster than the evidence• How obesity, alcohol consumption, sleep loss, and socioeconomic deprivation can affect testosterone• Whether pesticides, fluoride, plastics, deodorant ingredients, seed oils, or polyester clothing meaningfully affect testosterone• The relationship between red meat, cholesterol, saturated fat, and testosterone• Why many environmental and lifestyle factors matter more for overall health than for testosterone specifically• How the testosterone conversation also applies to women• Whether differences within the normal physiological testosterone range meaningfully affect muscle growth or health• Why temporary hormonal increases after strength training do not necessarily produce more muscle growth• Acute changes in testosterone, growth hormone, insulin, and cortisol• When someone should consider having their testosterone levels checked• Which health conditions should be evaluated alongside possible hormonal concerns• Why laboratory results need to be interpreted alongside symptoms and clinical context• Why testosterone replacement therapy can be both overprescribed and underprescribed• And much moreFollow Austin on Instagram:@austin_barbellmedicineCHAPTERS02:10 The Testosterone Decline Myth06:37 Breaking Down Viral Claims08:03 An Evidence-First Framework11:15 Sponsor: Active Life12:26 Rapid-Fire Testosterone Villains16:24 Saturated Fat and Testosterone20:06 The Real Risk From Plastics21:52 Sponsor: MacrosFirst22:55 Seed Oils and Testosterone33:08 The Health Factors That Matter Most35:15 Obesity, Sleep Apnea, and Testosterone36:47 Alcohol and Lifestyle Evaluation37:44 Sleep Loss and Testosterone38:46 Extreme Diets Versus the Big Levers40:35 Optimization Versus Real Life42:07 Symptoms and Clinical Probability44:28 Specific Versus Vague Symptoms46:57 Misdiagnosis and Proper Medical Workup49:50 Hormonal Responses to Strength Training55:10 Why Laboratory Results Need Context01:01:44 Women and Testosterone Therapy01:06:31 Why TRT Is Mis-Prescribed01:09:32 When to Test Your Testosterone01:11:31 Final Thoughts and Book RecommendationSUPPORT THE SHOWIf this episode helped you better understand testosterone, hormonal health, or testosterone replacement therapy:• Subscribe and check out more episodes• Share the episode on social media and tag @andrewcoatesfitness• Send it to someone who is worried that modern life is destroying their testosteroneFOLLOW ANDREW COATESInstagram: @andrewcoatesfitnesshttps://www.andrewcoatesfitness.comPARTNERS AND RESOURCESRP STRENGTH APPUse code COATESRP:https://www.rpstrength.com/coatesJUST BITE ME MEALSUse code ANDREWCOATESFITNESS for 10% off:https://justbitememeals.comMACROSFIRST — FREE PREMIUM TRIAL• Download MacrosFirst• Begin setting up your account• When asked, “How did you hear about us?” enter: ANDREWKNKG BAGS — 15% OFFhttps://www.knkg.com/Andrew59676VERSA GRIPPShttps://www.versagripps.com/andrewcoatesTRAINHEROIC — FREE 90-DAY TRIAL• Visit: https://www.trainheroic.com/liftfree• Reply to the email you receive or email trials@trainheroic.com• Let them know Andrew sent youL1 BIOMECHANICS AND ASSESSMENT COURSEUse code COATES:https://pro.activelifeprofessional.com/assessmentworkshopevents

In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE—come together to discuss key highlights and groundbreaking research presented at the 2026 meeting. They share expert insights across the bench-to-bedside spectrum, including basic science, clinical research, and the latest in diabetes care and education. Tune in for thoughtful reflections on what this year's findings mean for clinical practice and future research. Available now across all ADA professional podcast channels. Featured Podcasts: DOC Updates – ADA's podcast for primary care Diabetes Care "On Air" – From ADA's clinical research journal, Diabetes Care DiabetesBio – From ADA's flagship research journal, Diabetes The Points of CARE - The official podcast of Diabetes, Obesity, and CardioMetabolic CARE Join the Discussion with: Alice Cheng, MD – Co-host of Diabetes Care "On Air" Kirk Habegger, PhD – Co-host of DiabetesBio Michael Rickels, MD, MS – Co-host of Diabetes Care "On Air" Neil Skolnik, MD – Co-host of DOC Updates and Diabetes Day by Day Kevin Williams, PhD – Co-host of DiabetesBio Richard Beaser, MD – Co-host of The Points of CARE

CardioNerds Dr. Rohit Nathani, Dr. Atefeh Ghorbanzadeh, and Dr. Mariam Riad, discuss Obesity-related Heart Failure with Preserved Ejection Fraction (HFpEF) with Dr. John Ostrominski.  This episode was produced as part of the CardioNerds Academy curriculum by House Jones under the guidance of House Chief, Dr. Mariam Riad and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This episode highlights the diverse clinical phenotypes and complex, multifaceted pathophysiology of HFpEF. We take a deep dive into the therapeutic advances that represent paradigm shift in metabolic modulation aimed at improving outcomes in patients with HFpEF and metabolic syndrome. Audio editing by CardioNerds intern Pacey Wetstein. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls HFpEF is a constellation of symptoms often with different underlying pathophenotypes; cardiometabolic type is rising in incidence. Diagnosis is predominantly based on the clinical scenario along with supporting evidence from imaging modalities such as echocardiogram, cardiac MRI, and right heart catheterization. Cardiometabolic HFpEF is a complex syndrome characterized by dysregulated lipid metabolism, systemic inflammation, and hemodynamic abnormalities, all of which contribute to exercise intolerance and frailty. Lifestyle interventions, comorbidities management, and HFpEF therapeutics go hand in hand for comprehensive HFpEF care and offer opportunities for multispecialty collaboration to achieve optimal patient outcomes. References Ostrominski, J, Højbjerg Lassen, M, Butt, J. et al. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. JACC. 2025 Nov, 86 (20) 1760–1777.https://doi.org/10.1016/j.jacc.2025.08.012  Packer, M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. JACC. 2025 Oct, 86 (16) 1269–1373.https://doi.org/10.1016/j.jacc.2025.06.055 Ahmed, N., Dalmasso, C., Turner, M.B. et al. From fat to filter: the effect of adipose tissue-derived signals on kidney function. Nat Rev Nephrol 21, 417–434 (2025). https://doi.org/10.1038/s41581-025-00950-5 Alicic, R.Z., Neumiller, J.J. & Tuttle, K.R. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease. Nat Rev Nephrol 22, 265–282 (2026). https://doi.org/10.1038/s41581-025-01036-y Ostrominski, J, Harrington, J, Claggett, B. et al. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. JACC. 2025 Nov, 86 (20) 1781–1801.https://doi.org/10.1016/j.jacc.2025.08.039

Suboptimal sleep quality and quantity are associated with higher body mass index and more difficulty losing weight. In this podcast, JAMA Insights author Atul Malhotra, MD, from the University of California, San Diego, discusses evidence regarding sleep and obesity with JAMA Deputy Editor Mary McDermott, MD. Related Content: Sleep Health and Obesity

Naturopathic gastroenterologist Mark Davis, ND (FABNG), discusses his work in fecal microbiota transplantation (FMT), research, and integrative approaches to GI disease. Davis explains FMT history, screening criteria, delivery methods, how it differs from probiotics, and why it is highly effective for recurrent C. difficile (about a 90% durable cure), while noting FDA-approved products (Rebyota, Vowst) and off-label applications. He describes IRB-approved studies on naturopathic care for IBS and ulcerative colitis and a blinded project comparing consistency across 15–20 stool microbiome labs. The conversation covers evidence for diet in IBS/IBD (including SCD and a semi-vegetarian diet), low-FODMAP as a temporary tool, breath testing and relapse in SIBO, helminthic therapy options and legality, targeted probiotics (Saccharomyces boulardii, Akkermansia, soil-based species), enema therapies, indigo naturalis benefits and risks, saffron evidence for mood, telemedicine practice, and a crowdfunding platform for clinical trials.

Send us Fan MailFor decades we've measured obesity using one simple number on a scale - but what if that's the wrong metric? Today, one of the world's leading experts in genetics explains why the future of obesity medicine may not be about losing more weight, but about losing the right kind of fat while preserving the muscle that keeps us healthy.Dr. Erik Ingelsson, MD, PhD is a physician-scientist and internationally recognized leader in human genetics, genomics, and metabolic disease research. He currently serves as Chief Scientific Officer at Wave Life Sciences ( https://wavelifesciences.com/ ), where he leads the development of next-generation RNA medicines designed to address major unmet medical needs.Before joining Wave, Dr. Ingelsson served as Senior Vice President and Head of Target Discovery at GSK, where he led large-scale efforts integrating human genetics, functional genomics, computational biology, and molecular science to discover and validate new drug targets across therapeutic areas.Prior to his transition into industry, Dr. Ingelsson was Professor of Medicine at Stanford University, where his laboratory used human genetics and functional genomics to uncover new biological mechanisms underlying insulin resistance, obesity, metabolic disease, and cardiovascular risk.Over his career, Dr. Ingelsson has authored more than 400 peer-reviewed scientific publications and has become one of the leading voices in translating insights from human genetic variation into new medicines.At Wave, Dr. Ingelsson  is helping pioneer a new approach to obesity treatment: targeting the biology of harmful fat accumulation rather than simply focusing on the number on the scale.Today we'll discuss the genetics behind obesity, the promise of RNA medicines, why visceral fat may be the true therapeutic target, and whether the next generation of obesity treatments will move beyond weight loss toward healthier body composition.#Obesity #GLP1 #WeightLoss #VisceralFat #MetabolicHealth #RNAMedicine #Genetics #PrecisionMedicine #Longevity #HeartHealth #Diabetes #HumanGenetics #Biotechnology #DrugDiscovery #MuscleHealth #BodyComposition #CardiometabolicHealth #WaveLifeSciences #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

What happens inside skeletal muscle during obesity—and how can we protect lean mass while losing fat? The PSMF Library is officially live

80% of Americans are metabolically unhealthy, which means the obesity conversation isn't about weight for a lot of people... It's about internal health markers that indicate a declining state of metabolic function regardless of what someone weighs. Inside today's episode, I get into the harder version of the obesity conversation including whether it should be classified as a chronic medical condition, what happens when we label people as broken and then sell them the solution to their "brokenness", and where the personal responsibility conversation sits in a landscape flooded with GLP-1 medications and food environments engineered to defeat every mechanism the body has for satiety.Topics discussed: - The 80% Metabolically Unhealthy Statistic- Obesity as a Chronic Medical Condition- The Broken Mindset Trap- Personal Responsibility and Empowerment- Cardiovascular Risk, Longevity, and Children- Practices, Perceptions, and Physiology- Generational Parenting and Food Culture- The Chronic Dieting Flip Side---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Professor Donal O'Shea, Specialist in Obesity, discusses new research exploring the link between hair loss and the use of weightloss drugs.

People will say almost anything to justify unhealthy habits... and this livestream is another example.In today's reaction:

Dr. Gary McGowan drops in to share a masterclass on cardiovascular disease and its major risk factors, including:The relationship between cholesterol and cardiovascular diseaseWhy LDL cholesterol is importantWhat causes LDL cholesterol to riseThe dietary factors that can increase LDL cholesterolNavigating misleading claims about LDL from the carnivore diet communityWhy elimination diets can appear to improve someone's healthThe relationship between obesity and cardiovascular diseaseWhy not all fat storage in the body is associated with the same level of disease riskVisceral fat, BMI, and the personal fat thresholdWhy cardiovascular risk accumulates over timeThe role of genetics in cholesterol and blood pressureWhat causes high blood pressureThe role of dietary sodium in hypertensionThe most important lifestyle behaviours for lowering cardiovascular disease riskHow to screen for atherosclerotic plaque buildup in your arteriesCoronary artery calcium scans and CCTA imagingWhether caffeine and energy drinks increase the risk of heart problemsAnd much moreFollow Gary on Instagram:@drgarymcgowanCHAPTERS01:31 Cholesterol and Heart Risk04:50 Why LDL Rises06:23 Diet Drivers of LDL09:31 Coffee and Cholesterol10:32 Exercise and Lipids12:19 Carnivore LDL Debate18:32 Elimination Diet Reality21:48 Obesity and Heart Disease26:26 Visceral Fat and BMI31:15 BMI Reality Check32:24 Personal Fat Threshold32:46 Obesity Over Time33:58 Cumulative Risk Model34:58 Blood Pressure Drivers36:04 Salt and the Modern Diet38:21 Lifestyle Risk Pillars38:53 Heart Plaque Screening41:32 Calcium Scans Explained44:33 CCTA for Soft Plaque48:17 Caffeine and Heart Risk53:14 Energy Drink Extremes55:21 Where to Find Gary57:34 Final Wrap-UpSUPPORT THE SHOWIf this episode helped you better understand cholesterol, blood pressure, or cardiovascular disease risk, you can support the show by:Subscribing and checking out more episodesSharing it on social media — tag me and I'll respondSending it to someone who is confused about cholesterol, blood pressure, or heart healthFOLLOW ANDREW COATESInstagram: @andrewcoatesfitnesshttps://www.andrewcoatesfitness.comPARTNERS AND RESOURCESRP STRENGTH APPUse code COATESRP:https://www.rpstrength.com/coatesJUST BITE ME MEALSUse code ANDREWCOATESFITNESS for 10% off:https://justbitememeals.comMACROSFIRST – FREE PREMIUM TRIALDownload MacrosFirst and during setup you'll be asked:“How did you hear about us?”Type in the code: ANDREWKNKG BAGS – 15% OFFhttps://www.knkg.com/Andrew59676VERSA GRIPPShttps://www.versagripps.com/andrewcoatesTRAINHEROIC – FREE 90-DAY TRIALComplete these two steps:Go to:https://www.trainheroic.com/liftfreeReply to the email you receive — or email trials@trainheroic.com — and let them know Andrew sent you.L1 BIOMECHANICS AND ASSESSMENT COURSEUse code COATES:https://pro.activelifeprofessional.com/assessmentworkshopevents

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ultra-processed foods fuel obesity; GLP-1 drugs help reduce cravings, but long-term success still relies on healthy habits. #ObesityCrisis #FoodAddiction #GLP1Drugs #HealthyEating

Send us Fan MailAaron and Peaches sit down to talk Blue Angels flyovers, testosterone testing, military medicine, height-to-waist standards, and why the military has to get serious about health before people break.The episode starts with the Blue Angels beach flyover debate and whether something can be technically questionable while still being completely awesome. Then the guys get into the bigger conversation around the Department of War pushing testosterone checks for men over 30, why the military medical system has resisted basic hormone testing for years, and how operator syndrome, traumatic brain injuries, cortisol dysfunction, vitamin D deficiency, and low free testosterone can wreck performance and mental health.Aaron talks through his own fight to get blood work done, what the military missed, and why private-sector care finally helped him understand the difference between total testosterone and free testosterone.The conversation also hits height-to-waist standards, fat bodies in uniform, why some people will get flagged unfairly, and why most people need to stop making excuses. The bottom line: fitness is not just about looking good in uniform. It affects mental health, cognitive performance, readiness, durability, and who you become after the military.Check out Tasty Gains:TastyGains.comRegister for Operator Training Summit:OperatorTrainingSummit.comChapters:00:00 - Intro, Tasty Gains, and Operator Training Summit03:02 - Blue Angels Flyover Controversy03:39 - Unsafe vs. Inappropriate05:00 - Why Professionals Change the Risk Equation06:59 - Was the Flyover Necessary?08:22 - Pensacola, Nellis, and Airshow Culture09:20 - Testosterone Testing in the Military10:37 - What the Headlines Are Missing11:14 - Operator Syndrome and Low Testosterone12:11 - Fighting the Military Medical System12:55 - Vitamin D Deficiency in the Military14:34 - The Problem With “Normal” Testosterone Ranges16:00 - Trying to Raise Testosterone Naturally17:14 - Total Testosterone vs. Free Testosterone18:08 - TBI, Free Test, and Feeling Broken18:57 - Whoop Blood Work and Better Data19:19 - Breaking Down Institutional Resistance20:12 - Why This Could Lead to Better Screening21:02 - How the Referral System Fails People22:08 - Why Baseline Testing Matters22:34 - Trauma Medicine vs. Clinical Medicine23:55 - Military Medicine, COVID, and Bad Advice26:35 - Readiness Pressure and Medical Liability27:30 - SSRIs, Mental Health, and Missed Questions29:26 - The Military Health System Problem30:33 - Women, Hormones, and HRT30:42 - What to Ask Before Accepting Medication31:29 - Akron Bar Fight Story34:46 - Air Force Height-to-Waist Ratio35:11 - Body Composition Standards Come Back Around36:52 - Old BMI Standards and Fat Boy Programs37:19 - Height and Weight Charts39:41 - Peaches Tests the Calculator41:16 - When the Standard Misses Body Type42:40 - Trent's Monster Habit43:29 - Strategic Energy Drinks43:56 - Ten-Year-Old Crushes the Army PT Test45:30 - Kids, Discipline, and Internet Boundaries47:34 - Coaching Kids Through Hard Things48:25 - Wrestling Coach Motivation50:38 - Height-to-Waist and Job Performance51:40 - Human Performance and Mental Health52:34 - Obesity, COVID, and Comorbidities53:54 - Water, Sunlight, Nutrition, and Fitness55:26 - What People Cut First When Life Gets Busy55:42 - Sleep as a Performance Enhancer56:43 - Why Fitness Improves Mental Health58:26 - Confidence, Attraction, and Looking Better59:45 - Extrinsic Motivation Still Counts01:01:12 - Final Thoughts and Members-Only PreviewSupport the showJoin this channel to get access to perks: HEREBuzzsprout Subscription page:  HERERegister for our Operator Training Summit:  OperatorTrainingSummit.comFind an Air Force Recruiter: AirForce.comCollabs:Ones Ready - OnesReady.com 18A Fitness - Promo Code:  ONESREADY ATACLete - Follow the URL (no promo code):  ATACLeteDanger Close Apparel - Promo Code:  ONESREADYDFND Apparel...

In this episode, Nole and Kevin kick things off with a recap of Kevin's family trip to see Forrest Frank in Los Angeles, navigating the strange contrast of driving past old shooting and stabbing calls while the kids listen to worship music, mixed with some unfiltered thoughts on the absolute commercialism of modern Christian concerts ($100 t-shirts, anyone?).Then, the guys revisit a literal "hand grenade" question from a few weeks back: Can you be a good leader if you're obese? They pull no punches as they dive back into the uncomfortable truth about physical fitness, discipline, and why being afraid to hurt a brother's feelings can ultimately lead to watching them careen off a cliff. From the biblical charge to treat the body as a temple to the grit of summer "work hardening" in the heat, this conversation breaks down what we owe to our crews, our families, and ourselves. Finally, they tackle the shifting culture of the firehouse kitchen table, exploring how to guard camaraderie and tradition when everyone is on a different diet.Big thank you to My Epic and Facedown Records for the use of their song "Hail" in our podcast!https://www.youtube.com/watch?v=Dz2RZThURTU&ab_channel=FacedownRecordsThe Fire You Carry on YouTube.Sign up for a class at The Fire Up Program!https://www.fireupprogram.com/programsThe Fire Up Progam video.https://www.youtube.com/watch?v=I__ErPW46Ec&t=12s&ab_channel=FireUpProgramThe Fire You Carry Instagram.https://www.instagram.com/thefireyoucarry/Donate to The Fire Up Program.https://www.fireupprogram.com/donateThe Fire Up Program Instagram.https://www.instagram.com/fireup_program/Kevin's Instagram.https://www.instagram.com/kevinpwelsh/?hl=en

"Doc, do I need to take this forever?" It's one of the most common questions I hear in my office, whether it's someone's very first visit or someone who's already lost 30, 40, even 80 pounds and is feeling great. In this episode, I break down why your body fights so hard to regain weight after you lose it, and why that's biology, not failure. I walk through the new ATTAIN Maintain trial, a study of 376 adults who had already lost significant weight on tirzepatide or semaglutide, testing whether switching to an easier once-daily oral GLP-1 could help them keep the weight off, instead of just asking whether stopping medication causes regain. Maintenance isn't about staying on one medication forever. It's about having an individualized, active plan, and the ATTAIN Maintain data gives us more options than ever to build one. Episode Highlights: Why your metabolism and hunger hormones fight to reverse weight loss Lessons from the SURMOUNT-4 trial on what happens when treatment stops completely Inside the ATTAIN Maintain trial design and who was studied The weight maintenance results: oral medication vs. placebo Why maintenance therapy doesn't have to look like the treatment that got you there What actually goes into a sustainable long-term plan beyond medication Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

I told myself not to do it. I did it. I looked at my phone, got sucked in by my own curiosity, and was quickly reminded the world is overrun by axxholes, morons, and living demons.Subscribe over here, too: https://www.youtube.com/@WisdomFitnessAZGo to my site:https://SemperFryLLC.comCode: paratus for 15% OFF Exp. 7.31.2026BB Twittz: https://x.com/KristosCastJoin the Patreon with this link:https://www.patreon.com/c/KristosCastNew Channel on YT:https://www.youtube.com/@WisdomFitnessAZJoin Dr. Glidden's Membership site here:https://leavebigpharmabehind.com/?via=pgndhealth⁠Use Code: baalbusters for 25% OFFMake Dr. Glidden Your DoctorUse Code BB5 here for your 90 Essential Nutrients:https://www.azurestandard.com/shop/brand/azurewell/2326The Azure Whole Food Essential Nutrients are 1. Whole Food Multivitamin, 2. Alaskan Cod Liver Oil, 3. Fulvic-Humic Energy Blend, 4. IP6 Supreme. I also recommend adding the Core Copper.Use code BB5 for your discount.Be a Producer:https://GivesendGo.com/BaalBustershttps://buymeacoffee.com/BaalBustershttps://paypal.me/BaalBustersPodcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.

Do you have trouble sleeping? An occasional late night or early morning is probably not dangerous, but too many people get too little sleep on a regular basis. How does that affect their health? Even more importantly, what can they do to change the situation? You'll want to listen to find out if you need a sleep reset. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, July 18, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on July 20, 2026. The podcast will be available on Monday (July 20, 2026) Do You Need a Sleep Reset? Why is sleep so important for good health? Our guest is a sleep medicine specialist who uses a metaphor of Disneyland. Crucial maintenance on the theme park happens at night, when there are no visitors. Streets are cleaned, flower beds are weeded, and rides are inspected and, if needed, repaired. None of that can happen while the park is open for business. Our bodies and brains also need time for maintenance and repair, and some of that happens while we are sleeping. When we don't get the rest we need, we may find ourselves at increased risk for diabetes, cardiovascular problems, cancer, cognitive challenges and even premature death. Unfortunately, anxiety about not sleeping can keep people awake all on its own. How can people break that cycle? We'll also discuss ways that people can get help avoiding screens at night. That is an important part of a sleep reset. Blue light from the screen signals the brain to be alert instead of relax. Scrolling social media can often be emotionally upsetting, which also makes it more difficult to fall asleep. Is Your Diet Keeping You Awake? Most of us recognize that a big midnight snack, á la Dagwood Bumstead of the Blondie comic, is probably not conducive to sleeping well. How does nighttime eating affect our circadian rhythm? Are there diets that we should avoid because of their impact on sleep? Dr. Seheult describes a study in which volunteers had their sleep stages monitored closely during the time they were consuming different diets (Obesity, July 2023). When they followed a high-fat, high-sugar diet, it disturbed the pattern of their brain waves during what should have been restorative sleep. How Do Sleep Problems Affect Eating Habits? A lot of us are aware that when we are sleep deprived, we are more inclined to become hangry and we may be less discerning about what we eat. A recent study shows that the sleep deprivation can have an effect even if it is fairly mild and short-term. Scientists recruited people who normally sleep seven to eight hours a night and asked them to stay up an extra hour and a half (Annals of Internal Medicine, July 7, 2026).  During the six weeks of that part of the experiment, people were less active during the day. They also ate more, so they gained about a pound, on average, during those six weeks. Presumably, disrupting sleep for a longer period of time would result in greater weight gain and metabolic disruption. Would a Ketogenic Diet Help with a Sleep Reset? A ketogenic diet, in which the body relies on ketones rather than glucose for energy production, may be helpful. In particular, fasting overnight for at least 14 hours helps the body do what it must during sleep time. To figure out when you should stop eating, identify when you usually start to feel sleepy. That should be your bedtime. Having your last meal of the day about three hours before that will generally offer enough time for digestion so that you don't experience reflux in the middle of the night. Morning Light and Afternoon Naps Your sleep reset may depend on getting your own circadian rhythm to synchronize with the rest of the world. That is where early exposure to morning light comes in. It's beginning to feel a bit like The People's Pharmacy is on repeat: get morning light exposure! It sets your system up for feeling awake and alert during the day and starting to feel sleepy as the light fades in the evening. Obviously, this is most helpful for people who work during daylight hours. Those working overnight shifts would have to organize their days differently. People who have trouble falling asleep may be tempted to take a nap in the afternoon to make up for the lost sleep. That could be a mistake, as it relieves the sleep pressure that helps people fall asleep without trying. Learning to Fall Asleep If you interact with parents of very young children, you may have heard of sleep training. People have strong feelings about this, both pro and con. Adults rarely need sleep training, though. What we are more likely to need is “not-sleeping un-training.” Too many people approach the bedroom as though it were a stage, and sleep is the performance. No wonder they may develop some performance anxiety about sleeping! Other individuals have learned to associate the bedroom with tossing, turning and watching the clock. Consequently, their bodies tense up instead of relaxing when they get between the sheets. There is no easy quick fix for this problem, but cognitive behavior therapy for insomnia has been proven effective for most people. How About PM Pain Relievers? Even though there isn't an easy fix for sleep troubles, many people want one. They reach for the PM pain reliever and hope it will offer them a good night's sleep without a prescription. The “PM” part of that pain reliever is an old-fashioned antihistamine called diphenhydramine. You might be more familiar with its brand name: Benadryl. You'll also find it in Tylenol PM, Advil PM and all the other PM meds because it tends to make people feel drowsy. What's wrong with that? To start with, it isn't clear that it remains effective after a week or two. In addition, people with restless leg syndrome often find that it makes their condition worse. Other folks report that diphenhydramine can result in an unpleasant “hangover” the next day, in which they feel drowsy though not asleep for a good part of their waking hours. What Wakes You Up at Night? If your sleep problem is waking in the wee hours and having trouble getting back to sleep, you should consider the possibility that you have sleep apnea. The REM sleep of those early morning hours is not as deep as some other sleep stages. Consequently, an alarm signal from your brain saying you haven't taken a breath for 20 or 30 seconds may be more likely to wake you. Sleep apnea may be treated by providing air so that the pressure props the collapsing airway open. We discuss this in greater detail along with a new alternative to a CPAP machine in the podcast for this week. This Week’s Guest Dr. Roger Seheult is an Associate Clinical Professor at the University of California, Riverside School of Medicine. He is also an Assistant Clinical Professor at the School of Medicine and Allied Health at Loma Linda University. He is quadruple board-certified in Internal Medicine, Pulmonary Diseases, Critical Care Medicine, and Sleep Medicine through the American Board of Internal Medicine. His current practice is in Beaumont, California. He is a critical care physician, pulmonologist, and sleep physician at Optum California. Dr. Seheult lectures routinely across the country at conferences and for medical, PA, and RT societies. He is the director of a sleep lab and the Medical Director for the Crafton Hills College Respiratory Care Program. He is co-founder and presenter for MedCram.com, a site that offers concise and easy-to-follow medical videos on a range of topics. Roger Seheult, MD, MedCram, Loma Linda, UC-Riverside Listen to the Podcast The podcast of this program will be available Monday, July 20, 2026, after broadcast on July 18. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

"I always remember feeling like I was part of the clean plate club," says Dr. Christle Guevarra, recalling a childhood spent quietly convinced that her weight was a matter of willpower. That belief followed her through a competitive powerlifting career and medical practice until she finally tried a GLP-1 medication herself and, as she describes it, the constant mental noise around food quieted down. Now a board-certified family and sports medicine physician, traveling team doctor for U.S. Figure Skating, and author of The Beginner's Guide to GLP-1s, Dr. Guevarra brings a rare combination of clinical authority and lived experience to the conversation around obesity medicine.  In this episode of Raise the Line from Elsevier, host Lindsey Smith talks with her about what's actually changed in how physicians understand the issue and what it means for patients. "The biggest thing is reframing how we approach weight loss. It's not just a willpower problem, it is a neurobiological problem." Tune in to learn about: Why she said no to a GLP-1 prescription for two years and what finally changed her mind; The real story behind concerns about muscle loss on these medications; What happens when the “food noise" goes silent and a new set of challenges takes its place.   Mentioned in this episode:  Dr. Christle's website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

A new report from the Health and Social Care Committee says customers are being pushed towards products high in fat, sugar and salt which are typically cheaper than more nutritious food and that the government's food policy needs overhauling. The chair of the committee, Liberal Democrat MP Layla Moran, talks to Nuala McGovern about their recommendations.New analysis in The Economist suggests after years of progress fewer women are reaching executive positions and there may be signs that younger women are becoming less interested in promotion. Nuala McGovern speaks to the author of that analysis and a woman who left an executive role to rebalance her life. We hear from Sarah Ruggins who recently broke the world record for cycling the length of Europe - a distance of over 6,000 kilometres – double the length of the Tour de France. She only started cycling three years ago having spent a decade recovering from a condition that saw her bedridden and immobile – Complex Regional Pain Syndrome, one of medicine's most painful conditions. Sarah now holds three ultra-cycling records.Known at one point as the Diana of the Middle East and the rose of the desert, Asma al-Assad, the wife of Syrian President Bashar al-Assad, quickly became a well-known face around the world. But just how much do we know about the London-born former First Lady and the role she played in her dictator husband's oppressive dictatorship where peaceful protests against his regime were violently repressed, eventually leading to 13 years of civil war that saw more than half a million people killed. Nuala speaks to investigative journalist Chloe Hadjimatheou about her new podcast, We Call Her Emma. Presenter: Nuala McGovern Producer: Kirsty Starkey

Send us Fan MailBlood-brain barrier as a dynamic interface allowing selective passage of nutrients, peptides, and gut hormones.TOPICS DISCUSSED:Blood-Brain Barrier Structure: Capillary endothelial cells with tight junctions, absent fenestrae, and minimal vesicles create a selective interface; supported by astrocytes and pericytes.Crossing Mechanisms: Lipid-soluble small molecules diffuse passively; glucose, amino acids, and regulatory peptides use saturable transporters whose rates vary by need.Peptide Transport: Many peptides cross via lipid solubility or specific transporters; rate, not all-or-none presence, determines biological relevance; efflux systems remove some (e.g. certain enkephalins).Dynamic Regulation: Transporters for leptin and insulin are modulated by epinephrine, triglycerides, and brain demand; changes occur in aging and Alzheimer's (reduced glucose uptake, impaired Aβ efflux).Circumventricular Organs: Leaky capillary regions allow rapid sampling of blood signals while tanycytes limit spread to surrounding brain tissue.Drug Delivery Challenges: Small lipid-soluble drugs, barrier disruption (e.g. focused ultrasound), and “Trojan-horse” strategies each have limitations; intranasal delivery shows rapid brain distribution.Peptides & Brain Effects: Gut peptides like GLP-1 analogs, insulin, and ghrelin influence cognition and memory; brain entry predicts central effects.GUEST: William Banks, MD is a physician-scientist and leading researcher on the blood-brain barrier. He has focused on humoral brain-body communication, peptide transport, and the barrier's role in health and disease.RELATED CONTENT:M&M 298 | GLP-1s & Novel Peptides in Obesity, Diabetes & Metabolic Health | Katrin SvenssonSupport the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Are secondary VA claims getting denied more often in 2026? Has the VA changed the rules on secondary service connection?In this episode, we break down the truth about secondary VA claims, why the VA is scrutinizing nexus opinions more closely, and what veterans need to understand about medical evidence moving forward.We discuss: What secondary service connection actually means  The difference between causation and aggravation  Why weak nexus letters are getting challenged  Obesity as an intermediate step  Why some secondary claims succeed while others fail  The growing importance of detailed medical rationale  Common misconceptions veterans hear online  How strong medical evidence can impact VA appeals This episode is designed to help veterans better understand the medical side of secondary claims and the importance of evidence-based opinions in today's VA disability environment.Topics Covered Secondary VA claims in 2026  VA disability claims  Nexus letters  Aggravation claims  Sleep apnea secondary claims  Orthopedic secondary conditions  Medical evidence for VA claims  Independent medical opinions  Veteran disability appeals  VA claim denials About the PodcastThe Veterans Disability Nexus Podcast discusses VA disability medical evidence, nexus letters, DBQs, and the intersection of medicine and veterans disability claims. Hosted by medical professionals experienced in reviewing complex VA disability cases and independent medical opinions.DisclaimerThis podcast is for educational and informational purposes only and does not constitute legal or medical advice. Listening to this episode does not create a provider-patient relationship. Veterans should consult accredited representatives or qualified professionals regarding their individual claims or appeals.

Additional Resources:  ADCES Legislative Action Center OCAN Website OCAN Patient Roadmap  OCAN Advocacy Efforts Centers for Medicare and Medicaid Services (CMS) Website CMS GLP-1 Bridge FAQ CMS Eligibility website ADCES 2024 State Policy Forum Listen to more episodes of Diabetes Care Conversations at https://www.adces.org/practice/the-huddle-podcastLearn more about ADCES and the many benefits of membership at adces.org/join.The Diabetes Care Conversations Podcast is edited by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Dr. Andrew Hogan is a Professor and Principal Investigator of the Obesity Immunology Research Group at Maynooth University. He discusses how obesity drives chronic inflammation and immune dysfunction, increasing the risk of diseases such as diabetes and cancer, while highlighting the immune system’s role in disease progression. He also explains how GLP-1 therapies improve both metabolism and immune function, offering new insights into obesity treatment. Featured Products and Resources: Request your free EasySep sample and share your experience for a chance to win prizes worth up to $3,000! Win 350 US dollars or equivalent toward refreshments to fuel your journal club discussions. The Immunology Science Round Up Innate Immunity Predicts Symptoms – Stronger innate immune responses predisposed people to influenza symptoms while also promoting antiviral immune activation. Broad HIV Neutralization #1 – A novel HIV immunogen induced broadly neutralizing antibodies in macaques, providing a promising blueprint for HIV vaccine development. Broad HIV Neutralization #2 – A germline-targeting vaccine induced broadly neutralizing HIV antibodies in nonhuman primates. CAR-T Targets Glioblastoma – A dual-targeting CAR-T therapy achieved durable glioblastoma control in preclinical models. Image courtesy of Dr. Andrew Hogan Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Professor Donal O'Shea, HSE National Clinical Lead on Obesity

If you've seen headlines linking Ozempic and other GLP-1 medications to sudden eye strokes, I want to stop the panic right here.  In this episode, I break down what the research on NAION actually shows, who's really at risk, and why the scary relative-risk numbers you're seeing online don't tell the whole story. I walk you through what NAION is, why patients on semaglutide often already carry the underlying risk factors that get left out of the clickbait, and what the difference is between an observational study raising a signal and a randomized trial proving cause and effect. I also share the warning signs that mean you should go to the ER immediately, not wait for your next appointment. You'll walk away knowing exactly how to think about this headline, what questions to bring to your own doctor, and why staying on your medication is usually the right call. Episode Highlights: What NAION is and how it affects the optic nerve The risk factors patients on GLP-1s often already have What the 37-million-person study actually found — and didn't Why randomized trials tell a different story than observational data Absolute risk vs. relative risk, explained simply Warning signs that mean go to the ER now Why sleep apnea complicates the whole picture Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Jim Ryan, ABC News National Correspondent joins Megan Lynch to talk about the use of GLP-1's has reached a new high.

Send us Fan MailToday we're releasing a new episode from a brand new series called the Boundless Body Radio Heritage Series! I wanted to do something extra special to celebrate 1,000 podcast episodes recorded here at Boundless Body Radio, a milestone that we hit on June 24, 2026!These episodes are actually not new, although they might be new to you! When we first got started back in October, 2020, I was so fortunate that so many incredible people said "YES" to being hosted on the show, however, we didn't have very many listeners at the time!Today, we get thousands of downloads every single month, and are usually included in the top 150 Fitness and Nutrition Podcasts on the Apple Podcast charts!To honor our amazing guests, I will be selecting one of those original episodes and posting them here on for this special series!As I was going through these episodes again, I remembered how valuable these conversations actually were. it was really striking how much the information these experts have shared has born out to be even more accurate several years later.The audio quality of a show was not as good back then as it is now, but I still really hope you enjoy these episodes, and find them relevant and helpful to you today!Cheers, thanks as always for listening, and I really hope you enjoy this episode of the Boundless Body Radio Heritage Series!Ben Bikman, PhD, is a returning guest on our show! Be sure to check out his first appearance on Boundless Body Radio, way back on episode 30, which is the most popular episode we've ever recorded!His sensational book, Why We Get Sick: The Hidden Epidemic at the Root of Most Chronic Disease-and How to Fight It offers a thought provoking yet real solution to insulin resistance and suggests how readers can reverse pre-diabetes, improve brain function, shed fat, and prevent diabetes.Find Dr. Bikman at-IG- benbikmandphdInsulin IQFind Boundless Body at-myboundlessbody.comBook a session with us here! 

Some Americans are panicking at the recent so-called outbreak of "explosive diarrhea." The news is reporting hundreds of cases nationwide. But according to the AAFP, "acute diarrheal disease accounts for 179 million outpatient visits annually in the United States." So there is no sudden outbreak of disease, and the suppose culprit, the Cyclospora parasite, is only suspected but not proven to have caused the diarrhea. Strangely, a Meta data center recently dumped contaminated water into public sewers, spreading what they said was Cupriavidus gilardii, which can also cause diarrhea. Taco Bell, famous for its diarrhea aftereffects, has begun removing certain vegetables from their menu since produce is being blamed for the so-called outbreak. Whatever truth there may be to this should be overshadowed by the fact that produce is only contaminated because large scale in industrial farms often are polluted by animal agriculture, or animal feces is sprayed directly on the produce via collected water. Is it possible that this diarrhea is simply a byproduct of the poor American diet, severely deficient in fiber and burdened by excess protein. Both of these problems can separately cause diarrhea, but together are certainly essential cause. Other developed countries have a third the number of annual U.S. diarrhea cases. So what is happening?https://www.usatoday.com/story/graphics/2026/07/09/maps-explosive-diarrhea-outbreak-cyclosporiasis/90862952007/https://apnews.com/article/cyclospora-outbreak-michigan-31e5e0034d39e85c844065a2bd593ecbhttps://www.aafp.org/afp/2022/0700/acute-diarrheahttps://www.theguardian.com/us-news/2026/jul/08/meta-datacenter-ai-wyoming-waterhttps://nypost.com/2026/07/09/lifestyle/taco-bell-pulls-ingredients-off-menu-as-explosive-diarrhea-parasite-cases-surge/?sr_share=facebook&utm_source=facebook&utm_campaign=nypost&utm_medium=social&fbclid=IwY2xjawS9E9xleHRuA2FlbQIxMABicmlkETJuVDdFSUFWME1HWXF4U1dNc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHsE7Yg3iMVCLTmtIsf61LLM61x7QdmHwTLcDJjgZAG8eO4DkhF4mKH38-64b_aem_YV9NJe_qxxvUnK9FraFLbQ*The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below.

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

On this special episode of Inside Business recorded at EY's head office, host Ciarán Hancock is joined by Dr Harriet Treacy, founder and CEO of BeyondBMI, Ireland's first online medically led weight management and obesity clinic.She explains how frustration at the inefficiencies of healthcare systems was the catalyst in her decision to pivot from a medical doctor to an entrepreneur.Harriet is a finalist in the Emerging category for the 2026 EY Entrepreneur of the Year awards.Also on this episode, is Tommy Kearns, CEO and co-founder of customer engagement platform Xtremepush. The company helps legacy media transition to digital, and new companies that have emerged over the last decade or so. Tommy also outlines the pivotal role AI is playing in the company's present and future.Tommy is a finalist in the Established category for the 2026 EY Entrepreneur of the Year awards.Plus, we also hear from Roger Wallace, Head of Assurance & EY Entrepreneur of the Year Partner Lead at EY Ireland, on how AI is being implemented in the company's business – the level of investment needed and the impact on employee roles. Roger also highlights the value of our indigenous entrepreneurs against the backdrop of our economy being driven by overseas investment.Produced by John Casey. Hosted on Acast. See acast.com/privacy for more information.

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 dials?www.FindHonestCare.com/KimFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________While Kim takes time away following the loss of her sister, we're revisiting some of our most impactful conversations from Season 1. Thank you for supporting The Plus SideZ Podcast and this community during this time.Why do GLP-1 medications work when years of dieting and exercise often don't?In this episode, obesity medicine physician Dr. Matea Rentea explains why obesity is more than willpower. Through expert insight and a powerful patient story, we explore the science behind obesity, metabolism, hormones, and why "eat less, move more" often isn't enough.In this episode:• Why diets fail for many people living with obesity• How hormones and metabolism affect weight loss• Why GLP-1 medications work differently• The role of exercise, mental health, and weight stigma• Real patient experiences alongside evidence-based medicineWhether you're new to GLP-1s or have been with us since Season 1, this conversation remains one of our most requested episodes.This episode was originally recorded in Season 1. Medical information reflects what was known at the time of recording. Always talk with your healthcare provider before making medical decisions. Follow Dr. Rentea https://www.renteaclinic.com/ ______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Use Honest Care to Appeal GLP-1 Denials. Go to HonestCare.com/Kim  Honest Care can Appeal GLP-1 Denials. Go to FindHonestCare.com/Kim Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Send us Fan MailCan We Prevent Muscle Loss While Taking GLP-1 Weight-Loss Drugs?GLP-1 medications like Zepbound have changed the way we treat obesity. But as more people lose significant amounts of weight, another question has emerged:What happens to your muscle?It's normal to lose some lean mass—including muscle—during weight loss. But researchers are now asking whether preserving more muscle could improve long-term health, particularly as we age.In this episode, Dr. Eeks speaks with Dr. Richard Pratley, lead author of a new randomized, double-blind, placebo-controlled clinical trial investigating whether an investigational antibody called apitegromab can help preserve lean mass in people taking tirzepatide (Zepbound).Together they discuss:• Why people lose lean mass during weight loss• What "lean mass" actually means—and why it matters• Why muscle preservation has become one of the biggest new questions in obesity medicine• How apitegromab works by blocking myostatin—a protein that acts like a brake on muscle growth• The results of the study and how much lean mass participants preserved• Why preserving lean mass doesn't automatically mean preserving strength• Whether concerns about muscle loss on GLP-1 medications have become exaggerated• The importance of resistance training and adequate protein during weight loss• Whether future obesity treatment will focus less on body weight and more on body composition• The bigger question: Are we entering an era where one medication leads to another—or is there a better path???This conversation explores one of the most interesting—and practical—questions in obesity research today: Can we lose fat without sacrificing too much muscle?Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Have you ever looked in the mirror and wondered, "Why is it so much harder to lose weight than it used to be?" Maybe you've tried the diets... counted the calories... exercised faithfully... only to watch the scale refuse to budge. What if the problem isn't a lack of willpower? What if we've been asking the wrong question all along?Today on Call IT in With Dar, I'm joined by Dr. William Summers, a physician with more than 36 years of experience helping people understand the science behind obesity. As a board-certified OB/GYN and medical weight management specialist, Dr. Summers believes it's time we stop blaming ourselves and start recognizing obesity for what it truly is—a complex medical condition influenced by biology, hormones, metabolism, and our modern environment.  In this myth-busting conversation, we'll explore why obesity has become one of the greatest health challenges of our time, what new research is revealing, how medications like Ozempic and Mounjaro are changing the conversation, and most importantly, why compassion and understanding are far more powerful than guilt and shame.  Whether you're struggling with your own weight, supporting someone you love, or simply wanting to separate fact from fiction, this episode offers clarity, hope, and practical insight.  Let's come together for this important conversation about obesity! Call It in with Dar! Support the showFull Show Notes can be found at CallITInPodcast.comPhoto credit: Rebecca Lange Photography Music credit: Kevin MacLeod Incompetech.com (licensed under Creative Commons)  Production credit: Erin Schenke @ Emerald Support Services LLC.Grab Dar's Flight Deck Oracle Card DeckTake Dar's Archetype Quiz

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification.  Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients."  "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy fractyl.com Listen to the podcast here

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification.  Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients."  "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy fractyl.com Download the transcript here

Luis and Camille riff on GLP-1s. They are not a silver bullet, nor do they teach you how to relate to food, but they can be a great temporary auto regulator and bridge while a new food relationship is built. In an era of overfed and undernourished people, Luis and Camille talk about how to get nutritional needs met. Resmaa Menakem speaks about culture vs strategy. Diet culture is a strategy. Our six month Embodied Nutrition Slow group, starting July 7, slowly and sustainably shifts the culture of how you relate to your body and what you consume. https://www.holisticlifenavigation.com/slow-practice-nutrition-groupContact us at info@holisticlifenavigation.com if you have any questions about the Embodied Nutrition Slow Group. You can get instant access to all of the HLN webinars and video courses here: https://hln.thinkific.com/collections You can order the book here: https://www.holisticlifenavigation.com/the-book----You can learn more on the website: https://www.holisticlifenavigation.com/You can follow Luis on Instagram @holistic.life.navigationQuestions? You can email us at info@holisticlifenavigation.com

Are they getting SWOLE AF in Vietnam? Are deadlifts necessary or are there other good options out there, what to do for knee issues and some Balls Deep videos that are hilarious. ALL LINKS: https://swolenormous.com

Obesity treatment has changed dramatically over the past decade. While nutrition and lifestyle remain the foundation of long-term metabolic health, today's medical landscape also includes bariatric surgery and GLP-1 medications as potential tools for certain individuals. In this episode, I sit down with board-certified bariatric surgeon and obesity medicine specialist Dr. Betsy Dovec to discuss how obesity treatment has evolved, who may benefit from bariatric surgery, how today's procedures differ from common misconceptions, and where GLP-1 medications fit into the conversation. Whether you've considered surgery yourself, are curious about today's obesity treatments, or simply want to better understand the options available, this episode offers a thoughtful, balanced discussion focused on long-term health—not just weight loss. In This Episode We Discuss: How bariatric surgery has changed over the years Who may be an appropriate candidate for weight loss surgery Common myths and misconceptions about bariatric surgery The role of GLP-1 medications in modern obesity treatment Why preserving muscle mass is essential during weight loss What happens when GLP-1 medications are discontinued The importance of protein, resistance training, and medical follow-up Looking beyond the scale to prioritize metabolic health and longevity Learn More About Dr. Betsy Dovec Website: https://bodybybariatrics.com/ Resources Mentioned ⭐ Feel Great System https://shanahussinwellness.com/feel-great-system/ ⭐ 90-Day Metabolic Reset https://shanahussinwellness.com/90-day-reset/ Let's Connect! Website: https://shanahussinwellness.com/ Instagram: https://www.instagram.com/shana.hussin.rdn/ Facebook: https://www.facebook.com/FastToHealWithShanaHussin My Courses & Programs ✔ Low Insulin Academy https://shanahussinwellness.com/programs-courses/low-insulin-academy-on-demand/ ✔ Cortisol Calm https://shanahussinwellness.com/programs-courses/cortisol-calm-signature-course/ If you enjoyed today's conversation, please share this episode with a friend or family member and consider leaving a rating and review. Your support helps us continue bringing you evidence-based conversations that empower you to take control of your metabolic health.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gluttony, stress, exhaustion, and unhealthy habits are often treated as merely physical problems. In this episode, Costi Hinn explains why these issues have spiritual implications and how believers can pursue a healthier, more faithful life.